Takeda Pharmaceutical Co Stock Filter Stocks by Fundamentals
| TAK Stock | USD 13.38 0.02 0.15% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
Takeda | Shares Owned by Institutions |
Takeda Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Takeda Pharmaceutical from analyzing Takeda Pharmaceutical's financial statements. These drivers represent accounts that assess Takeda Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Takeda Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5T | 3.2T | 2.7T | 3.4T | 3.9T | 4.7T | |
| Enterprise Value | 7.0T | 6.8T | 6.2T | 7.3T | 6.5T | 3.8T |
Takeda Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in Takeda Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Takeda Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Takeda Pharmaceutical's value.| Shares | Northern Trust Corp | 2023-12-31 | 1.8 M | Blackrock Inc | 2023-12-31 | 1.8 M | Managed Asset Portfolios, Llc | 2023-12-31 | 1.8 M | Envestnet Asset Management Inc | 2023-12-31 | 1.6 M | Causeway Capital Management Llc | 2023-12-31 | 1.3 M | Van Eck Associates Corporation | 2023-12-31 | 1.3 M | Y.d. More Investments Ltd | 2023-12-31 | 1.3 M | Jane Street Group, Llc | 2023-12-31 | 1.1 M | Old Mission Capital Llc | 2023-12-31 | 1 M | Capital Research Global Investors | 2023-12-31 | 14.3 M | Goldman Sachs Group Inc | 2023-12-31 | 8.6 M |
Takeda Fundamentals
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.94 T | ||||
| Shares Outstanding | 3.14 B | ||||
| Shares Owned By Institutions | 2.66 % | ||||
| Number Of Shares Shorted | 8.12 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.03 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 1.21 T | ||||
| Net Income | 317.04 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 4.38 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,297 X | ||||
| Cash Flow From Operations | 977.16 B | ||||
| Short Ratio | 5.26 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Price To Earnings To Growth | 3.23 X | ||||
| Target Price | 18.37 | ||||
| Number Of Employees | 49.09 K | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 41.92 B | ||||
| Total Asset | 13.96 T | ||||
| Retained Earnings | 1.54 T | ||||
| Working Capital | (83.98 B) | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 13.96 T | ||||
| Last Dividend Paid | 184.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.36 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.